Comments
Loading...
Inozyme Pharma Analyst Ratings and Price Targets | NASDAQ:INZY | Benzinga
Inozyme Pharma Inc has a consensus price target of $15.91 based on the ratings of 11 analysts. The high is $30 issued by Piper Sandler on January 13, 2025. The low is $6 issued by Jefferies on March 23, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and Raymond James on April 10, 2025, April 8, 2025, and March 12, 2025, respectively. With an average price target of $14.33 between HC Wainwright & Co., Needham, and Raymond James, there's an implied 1233.33% upside for Inozyme Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
Raymond James
Piper Sandler
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Inozyme Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | 1388.37% | HC Wainwright & Co. | Edward White50% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | 1295.35% | Needham | Joseph Stringer51% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 1016.28% | Raymond James | Ryan Deschner66% | $24 → $12 | Maintains | Outperform | Get Alert |
| 03/11/2025 | Buy Now | 2039.53% | Piper Sandler | Allison Bratzel65% | $30 → $23 | Maintains | Overweight | Get Alert |
| 03/11/2025 | Buy Now | 1295.35% | Needham | Joseph Stringer51% | $23 → $15 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 1388.37% | HC Wainwright & Co. | Edward White50% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 2690.7% | Piper Sandler | Christopher Raymond55% | $43 → $30 | Maintains | Overweight | Get Alert |
| 01/13/2025 | Buy Now | 923.26% | Wells Fargo | Tiago Fauth42% | $14 → $11 | Maintains | Overweight | Get Alert |
| 01/13/2025 | Buy Now | 1388.37% | HC Wainwright & Co. | Edward White50% | $14 → $16 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 1388.37% | HC Wainwright & Co. | Edward White50% | $14 → $16 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 1202.33% | HC Wainwright & Co. | Edward White50% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2024 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 10/25/2024 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 10/25/2024 | Buy Now | 1202.33% | HC Wainwright & Co. | Edward White50% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 09/30/2024 | Buy Now | 1295.35% | Wedbush | David Nierengarten63% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2024 | Buy Now | 1388.37% | Stifel | Dae Gon Ha47% | → $16 | Initiates | → Buy | Get Alert |
| 08/13/2024 | Buy Now | 1481.4% | Jefferies | Maury Raycroft32% | $16 → $17 | Assumes | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 1202.33% | HC Wainwright & Co. | Edward White50% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2024 | Buy Now | 1295.35% | Wedbush | David Nierengarten63% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 07/02/2024 | Buy Now | 1202.33% | HC Wainwright & Co. | Edward White50% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 1202.33% | Wells Fargo | Tiago Fauth42% | → $14 | Initiates | → Overweight | Get Alert |
| 05/08/2024 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 1202.33% | B of A Securities | Tazeen Ahmad54% | $16 → $14 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 1388.37% | HC Wainwright & Co. | Edward White50% | $16 → $16 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2024 | Buy Now | 1295.35% | Wedbush | David Nierengarten63% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | 1295.35% | Wedbush | David Nierengarten63% | → $15 | Maintains | Outperform | Get Alert |
| 08/09/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 1388.37% | HC Wainwright & Co. | Edward White50% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 1388.37% | HC Wainwright & Co. | Edward White50% | $19 → $16 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | → Buy | Get Alert |
| 03/23/2023 | Buy Now | 458.14% | Jefferies | Suji Jeong26% | $4.5 → $6 | Upgrade | Hold → Buy | Get Alert |
| 03/23/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | 1760.47% | HC Wainwright & Co. | Edward White50% | → $20 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | 2039.53% | Needham | Joseph Stringer51% | → $23 | Reiterates | → Buy | Get Alert |
| 05/26/2022 | Buy Now | 365.12% | Jefferies | Suji Jeong26% | → $5 | Initiates | → Hold | Get Alert |
| 05/11/2022 | Buy Now | 1760.47% | HC Wainwright & Co. | Edward White50% | $33 → $20 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Inozyme Pharma (INZY) stock?
The latest price target for Inozyme Pharma (NASDAQ:INZY) was reported by HC Wainwright & Co. on April 10, 2025. The analyst firm set a price target for $16.00 expecting INZY to rise to within 12 months (a possible 1388.37% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inozyme Pharma (INZY)?
The latest analyst rating for Inozyme Pharma (NASDAQ:INZY) was provided by HC Wainwright & Co., and Inozyme Pharma reiterated their buy rating.
When was the last upgrade for Inozyme Pharma (INZY)?
The last upgrade for Inozyme Pharma Inc happened on March 23, 2023 when Jefferies raised their price target to $6. Jefferies previously had a hold for Inozyme Pharma Inc.
When was the last downgrade for Inozyme Pharma (INZY)?
There is no last downgrade for Inozyme Pharma.
When is the next analyst rating going to be posted or updated for Inozyme Pharma (INZY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Inozyme Pharma (INZY) correct?
While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a reiterated with a price target of $16.00 to $16.00. The current price Inozyme Pharma (INZY) is trading at is $1.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
